O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

Introduction: CRICKET (NCT02296203) was designed to investigate the activity of the rechallenge with cet and iri as 3 rd -line treatment in RAS/BRAF wild-type mCRC pts with acquired resistance to 1^st-line cet- and iri-based therapy. The role of liquid biopsies as a tool to identify pts more likely to benefit from this strategy was investigated.